Month: May 2024

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll HPV16-positive high-risk patients with locally advanced cervical cancer undergoing chemoradiotherapy. VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. The cancer vaccine is built on Nykode’s technology platform...

Aspo PlcStock Exchange ReleaseOther information disclosed according to the rules of the ExchangeMay 14, 2024, at 8:05 a.m. Aspo’s financial targets and dividend policy updated, and profitability metric of the guidance changed Aspo holds a Capital Markets Day today, May 14, 2024, starting at 9.30 a.m. [(EEST)] in Helsinki. Aspo Group’s new portfolio vision, disclosed earlier today, along with the adjusted long-term financial targets, ESG commitment, business strategies, dividend policy as well as current state of Aspo’s business operations and prospects will be presented at the event. Revised financial targets Aspo’s long-term financial targets remain fundamentally unchanged, but they have been slightly adjusted to consider the compounder strategy and management of growth financing. Key changes include change from operating...

The shares in Belships ASA will be traded ex dividend NOK 0.60 from today, 14 May 2024. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

On the backdrop of a strong increase in business volumes, April for LHV was characterised by high profitability, with results still being driven by the growing loan portfolio and the interest income earned. It was a strong month for all companies of the Group. In April, AS LHV Group’s consolidated deposits grew by EUR 236 million, and the consolidated loan portfolio by EUR 94 million. The volume of the funds managed by LHV grew by EUR 23 million in April. A total of 6 million payments related to financial intermediaries were made in the month. In April, AS LHV Group earned EUR 15.8 million in consolidated net profit. AS LHV Pank generated EUR 13 million in net profit, AS LHV Bank Ltd EUR 1.3 million, AS LHV Varahaldus EUR 259 thousand, and AS LHV Kindlustus EUR 64 thousand. In April, the return on equity attributable to the shareholders...

Aspo PlcStock Exchange ReleaseInside informationMay 14, 2024, at 8:00 a.m. Inside information: Aspo’s new strategic portfolio vision Aspo will pursue a new portfolio vision of forming two separate companies in the coming years: Aspo Compounder and Aspo Infra. Considering the diverging business models and strategies with different ESG agendas, ESL Shipping would belong to ‘Aspo Infra’ and Telko and Leipurin would belong to ‘Aspo Compounder’. The business models between Aspo Compounder and Aspo Infra differ across multiple dimensions such as type of growth investments capex needs, business time span, funding needs, and ESG agenda, and will further diverge when implementing the selected business strategies. Aspo’s ambition is to aim to reach EUR 1 billion in net sales and 8% of EBITA (*) in 2028. This ambition for year 2028 is split...

Press ReleaseVELIZY-VILLACOUBLAY, France — May 14, 2024 JLR and Dassault Systèmes Extend Partnership, Deploying the 3DEXPERIENCE Platform for All Vehicle Programs WorldwideFive-year partnership marks the next phase of their long-standing collaboration to drive the automaker’s transformation for a good and responsible business More than 18,000 users globally will utilize virtual twins to increase the efficiency of vehicle engineering and digital manufacturing, save time, and reduce waste and costs The 3DEXPERIENCE platform connects all stakeholders in one collaborative virtual environment, leveraging the latest technological innovationDassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that it has extended its long-term strategic partnership with JLR for five years, heralding a new era of digital transformation...

Q1 2024 Earnings Highlights:Revenue, gains, and other income increased by 216% YoY Over 4x YoY increase in adjusted EBITDA Total comprehensive income increased by over 11x YoY14th May 2024 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment company specialising in digital assets, has today published its results for the quarter ending 31st March 2024. Jean-Marie Mognetti, Chief Executive Officer of CoinShares said: “Q1 2024 stands out as our strongest quarter ever, marking a period of unprecedented strength and profitability for CoinShares. This quarter reflects not only our robust financial performance but also highlights our enhanced strategic growth capabilities, exemplified by the successful acquisition of Valkyrie’s...

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024. The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations. The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: https://event.webcasts.com/starthere.jsp?ei=1670178&tp_key=4faf9c3758 About Nykode TherapeuticsNykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and...

Bíldudalur, 14th of May 2024 Icelandic Salmon is the parent company of Arnarlax, and other subsidiaries involved in salmon farming and processing in Iceland. The companies are collectively referred to as “Icelandic Salmon” or the “Group”. Operations In the first quarter 2024, Icelandic Salmon harvested 2,769 tonnes compared to 6,572 tonnes in the same quarter last year. The lower volume follows months of extraordinary harvesting at the end of last year, when biological challenges prompted the company to harvest early for animal welfare reasons. There was biological challenges in the first quarter this year. Mortality rate in the 2023 generation in the sea and at one of the smolt facilities was unusually high, resulting in one-off costs of EUR 3.6 million in the period. “During this winter, our team has had to face...